Decision support systems for personalized and participative radiation oncology

Advanced Drug Delivery Reviews

Volumn 109, Issue , 2017, Pages 131-153

  Lambin, Philippe ^a   Zindler, Jaap ^a   Vanneste, Ben G L ^a   De Voorde, Lien Van ^a   Eekers, Daniëlle ^a   Compter, Inge ^a   Panth, Kranthi Marella ^a   Peerlings, Jurgen ^a   Larue, Ruben T H M ^a   Deist, Timo M ^a   Jochems, Arthur ^a   Lustberg, Tim ^a   van Soest, Johan ^a   de Jong, Evelyn E C ^a   Even, Aniek J G ^a   Reymen, Bart ^a   Rekers, Nicolle ^a   van Gisbergen, Marike ^a   Roelofs, Erik ^a   Carvalho, Sara ^a   Leijenaar, Ralph T H ^a   Zegers, Catharina M L ^a   Jacobs, Maria ^a   van Timmeren, Janita ^a   Brouwers, Patricia ^a   Lal, Jonathan A ^a   Dubois, Ludwig ^a   Yaromina, Ala ^a   Van Limbergen, Evert Jan ^a   Berbee, Maaike ^a   van Elmpt, Wouter ^a   Oberije, Cary ^a   Ramaekers, Bram ^a   Dekker, Andre ^a   Boersma, Liesbeth J ^a   Hoebers, Frank ^a   Smits, Kim M ^a   Berlanga, Adriana J ^a   Walsh, Sean ^a   more..

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Decision support systems; Prediction models; Radiotherapy; Shared decision making

Indexed keywords

ARTIFICIAL INTELLIGENCE; DECISION MAKING; FORECASTING; MEDICAL IMAGING; ONCOLOGY; QUALITY ASSURANCE; RADIOTHERAPY;

ACCURATE PREDICTION; CLINICAL DECISION SUPPORT SYSTEMS; INITIAL DEVELOPMENT; NORMAL-TISSUE TOXICITY; PREDICTION MODEL; QUALITY ASSURANCE PROCEDURES; RADIATION ONCOLOGY; SHARED DECISION MAKINGS;

DECISION SUPPORT SYSTEMS;

ACCESS TO INFORMATION; CANCER RADIOTHERAPY; CLINICAL DECISION SUPPORT SYSTEM; COST EFFECTIVENESS ANALYSIS; DECISION SUPPORT SYSTEM; HUMAN; INFORMATION DISSEMINATION; INFORMATION PROCESSING; INFORMATION TECHNOLOGY; MACHINE LEARNING; METHODOLOGY; PARTICIPATORY MANAGEMENT; PERSONALIZED MEDICINE; PREDICTION; QUALITY CONTROL; RADIATION DOSE; RADIOSENSITIVITY; REVIEW; SHARED DECISION MAKING; TREATMENT OUTCOME; TREATMENT RESPONSE; NEOPLASM; PROCEDURES; RADIATION ONCOLOGY;

DECISION SUPPORT SYSTEMS, CLINICAL; HUMANS; NEOPLASMS; PRECISION MEDICINE; RADIATION ONCOLOGY; TREATMENT OUTCOME;

EID: 84956662833     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.01.006     Document Type: Review

References (317)

1. [1] Vogelzang, N., Benowitz, S., Adams, S., Aghajanian, C., Chang, S., Dreyer, Z., Janne, P., Ko, A., Masters, G., Odenike, O., Patel, J., Roth, B., Samlowski, W., Seidman, A., Tap, W., Temel, J., Von Roenn, J., Kris, M., Clinical cancer advances 2011: annual report on progress against cancer from the American Society of Clinical Oncology. J. Clin. Oncol. 30 (2012), 88–109.
2. [2] Abernethy, A., Etheredge, L., Ganz, P., Wallace, P., German, R., Neti, C., Bach, P., Murphy, S., Rapid-learning system for cancer care. J. Clin. Oncol. 28 (2010), 4268–4274.
3. [3] Maitland, L., Schilsky, L., Clinical trials in the era of personalized oncology. CA Cancer J. Clin. 61 (2011), 365–381.
4. [4] Rosenstein, B., West, C., Bentzen, S., Alsner, J., Andreassen, C., Azria, D., Barnett, G., Baumann, M., Burnet, N., Chang-Claude, J., Chuang, E., Coles, C., Dekker, A., Ruyck, K.D., Ruysscher, D. De, Drumea, K., Dunning, A., Easton, D., Eeles, R., Fachal, L., Gutierrez-Enrıquez, S., Haustermans, K., Henrıquez-Hernandez, L., Imai, T., Jones, G., Kerns, S., Liao, Z., Onel, K., Ostrer, H., Parliament, M., Pharoah, P., Rebbeck, T., Talbot, C., Thierens, H., Vega, A., Witte, J., Wong, P., Zenhausern, F., Radiogenomics: radiobiology enters the era of big data and team science. Int. J. Radiat. Oncol. Biol. Phys. 89 (2014), 710–713.
5. [5] Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N.J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I.F., Fojo, T., Siderov, J., Williamson, S., Camporesi, S., McVie, J.G., Purushotham, A.D., Naredi, P., Eggermont, A., Brennan, M.F., Steinberg, M.L., Ridder, M.D., McCloskey, S.A., Verellen, D., Roberts, T., Storme, G., Hicks, R.J., Ell, P.J., Hirsch, B.R., Carbone, D.P., Schulman, K.A., Catchpole, P., Taylor, D., Geissler, J., Brinker, N.G., Meltzer, D., Kerr, D., Aapro, M., Delivering affordable cancer care in high-income countries. Lancet Oncol. 12 (2011), 933–980.
6. [6] Gerlinger, M., Rowan, A., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., Varela, I., Phillimore, B., Begum, S., McDonald, N., Butler, A., Jones, D., Raine, K., Latimer, C., Santos, C., Nohadani, M., Eklund, A., Spencer-Dene, B., Clark, G., Pickering, L., Stamp, G., Gore, M., Szallasi, Z., Downward, J., Futreal, A., Swanton, C., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366 (2012), 883–892.
7. [7] Alizadeh, A.A., Aranda, V., Bardelli, A., Blanpain, C., Bock, C., Borowski, C., Caldas, C., Califano, A., Doherty, M., Elsner, M., Esteller, M., Fitzgerald, R., Korbel, J.O., Lichter, P., Mason, C.E., Navin, N., Pe'er, D., Polyak, K., Roberts, C.W., Siu, L., Snyder, A., Stower, H., Swanton, C., Verhaak, R.G., Zenklusen, J.C., Zuber, J., Zucman-Rossi, J., Toward understanding and exploiting tumor heterogeneity. Nat. Med. 21 (2015), 846–853.
8. [8] Bachtiary, B., Boutros, P., Pintilie, M., Shi, W., Bastianutto, C., Li, J., Schwock, J., Zhang, W., Penn, L., Jurisica, I., Fyles, A., Liu, F., Gene expression profiling in cervical cancer: an exploration of intratumor heterogeneity. Clin. Cancer Res. 12 (2006), 5632–5640.
9. [9] Boyd, C., Benarroch-Gampel, J., Sheffield, K., Cooksley, C., Riall, T., 415 patients with adenosquamous carcinoma of the pancreas: a population-based analysis of prognosis and survival. J. Surg. Res. 174 (2012), 12–19.
10. [10] Milosevic, M., Fyles, A., Wong, R., Pintilie, M., Kavanagh, M., Levin, W., Manchul, L., Keane, T., Hill, R., Interstitial fluid pressure in cervical carcinoma: within tumor heterogeneity, and relation to oxygen tension. Cancer 82 (1998), 2418–2426.
11. [11] Curtis, C., Shah, S., Suet-Feung, C., Turashvili, G., Rueda, O., Dunning, M., Speed, D., Lynch, A., Samarajiwa, S., Yuan, Y., Gräf, S., Ha, G., Haffari, G., Bashashati, A., Russell, R., McKinney, S., Langerød, A., Green, A., Provenzano, E., Wishart, G., Pinder, S., Watson, P., Markowetz, F., Murphy, L., Ellis, I., Purushotham, A., Børresen-Dale, A., Brenton, J., Tavaré, S., Caldas, C., Aparicio, S., The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 468 (2012), 346–352.
12. [12] Aerts, H., Bussink, J., Oyen, W., van Elmpt, W., Folgering, A., Emans, D., Velders, M., Lambin, P., De Ruysscher, D., Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation. Lung Cancer 75 (2012), 73–76.
13. [13] Aerts, H., van Baardwijk, A., Petit, S., Offermann, C., Loon, J., Houben, R., Dingemans, A., Wanders, R., Boersma, L., Borger, J., Bootsma, G., Geraedts, W., Pitz, C., Simons, J., Wouters, B., Oellers, M., Lambin, P., Bosmans, G., Dekker, A., De Ruysscher, D., Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose–PET–CT scan. Radiother. Oncol. 91 (2009), 386–392.
14. [14] Suit, H., Skates, S., Taghian, A., Okunieff, P., Efird, J., Clinical implications of heterogeneity of tumor response to radiation therapy. Radiother. Oncol. 25 (1992), 251–260.
15. [15] Roelofs, E., Persoon, L., Nijsten, S., Wiessler, W., Dekker, A., Lambin, P., Benefits of a clinical data warehouse with data mining tools to collect data for a radiotherapy trial. Radiother. Oncol. 108 (2013), 174–179.
16. [16] Roelofs, E., Dekker, A., Meldolesi, E., van Stiphout, R.G., Valentini, V., Lambin, P., International data-sharing for radiotherapy research: an open-source based infrastructure for multicentric clinical data mining. Radiother. Oncol. 110 (2014), 370–374.
17. [17] Vickers, A., Prediction models: revolutionary in principle, but do they do more good than harm?. J. Clin. Oncol. 29 (2011), 2951–2952.
18. [18] Dehing-Oberije, C., Yu, S., De Ruysscher, D., Meersschout, S., van Beek, K., Lievens, Y., van Meerbeeck, J., De Neve, W., Rao, B., van der Weide, H., Lambin, P., Development and external validation of a prognostic model for 2-year survival of non-small cell lung cancer patients treated with chemoradiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 74, 2009, 8.
19. [19] Egelmeer, A., Velazquez, E., de Jong, J., Oberije, C., Geussens, Y., Nuyts, S., Kremer, B., Rietveld, D., Leemans, C., de Jong, M., Rasch, C., Hoebers, F., Homer, J., Slevin, N., West, C., L. P., Development and validation of a nomogram for prediction of survival and local control in laryngeal carcinoma patients treated with radiotherapy alone: a cohort study based on 994 patients. Radiother. Oncol. 100 (2011), 108–115.
20. [20] Jimenez, M., van Baardwijk, A., Aerts, H., De Ruysscher, D., Novoa, N., Varela, G., L. P., Effectiveness of surgery and individualized high-dose hyperfractionated accelerated radiotherapy on survival in clinical stage I non-small cell lung cancer. A propensity score matched analysis. Radiother. Oncol. 97:93 (2010), 413–417.
21. [21] Lambin, P., Rios-Velazquez, E., Leijenaar, R., Carvalho, S., van Stiphout, R.G., Granton, P., Zegers, C.M., Gillies, R., Boellard, R., Dekker, A., Aerts, H.J., Radiomics: extracting more information from medical images using advanced feature analysis. Eur. J. Cancer 48 (2012), 441–446.
22. [22] Roelofs, E., Engelsman, M., Coen, R., Persoon, L., Sima, Q., Ruysscher, D. de, Verhaegen, F., Pijls-Johannesma, M., Lambin, P., Results of a multicentric in silico clinical trial (ROCOCO) comparing radiotherapy with photons and protons for non-small cell lung cancer. J. Thorac. Oncol., 7, 2012.
23. [23] Lambin, P., Stiphout, R. van, Starmans, M., Rios-Velazquez, E., Nalbantov, G., Aerts, H., Predicting outcomes in radiation oncology—multifactorial decision support systems. Nat. Rev. Clin. Oncol., 10, 2013.
24. [24] Deasy, J.O., Bentzen, S.M., Jackson, A., Ten Haken, R.K., Yorke, E.D., Constine, L.S., Sharma, A., Marks, L.B., Improving normal tissue complication probability models: the need to adopt a “data-pooling” culture. Int. J. Radiat. Oncol. Biol. Phys. 76 (2010), S151–S154.
25. [25] Skripcak, T., Belka, C., Bosch, W., Brink, C., Brunner, T., Budach, V., Büttner, D., Debus, J., Dekker, A., Grau, C., Gulliford, S., Hurkmans, C., Just, U., Krause, M., Lambin, P., Langendijk, J., Lewensohn, R., Lühr, A., Maingon, P., Masucci, M., Niyazi, M., Poortmans, P., Simon, M., Schmidberger, H., Spezi, E., Stuschke, M., Valentini, V., Verheij, M., Whitfield, G., Zackrisson, B., Zips, D., Baumann, M., Creating a data exchange strategy for radiotherapy research: towards federated databases and anonymised public datasets. Radiother. Oncol. 113 (2014), 303–309.
26. [26] Schilsky, R.L., Michels, D.L., Kearbey, A.H., Yu, P.P., Hudis, C.A., Building a rapid learning health care system for oncology: the regulatory framework of CancerLinQ. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 32 (2014), 2373–2379.
27. [27] Budin-Ljosne, I., Burton, P., Isaeva, J., Gaye, A., Turner, A., Murtagh, M.J., Wallace, S., Ferretti, V., Harris, J.R., DataSHIELD: an ethically robust solution to multiple-site individual-level data analysis. Public Health Genomics 18 (2015), 87–96.
28. [28] Meldolesi, E., van Soest, J., Dinapoli, N., Dekker, A., Damiani, A., Gambacorta, M., Valentini, V., An umbrella protocol for standardized data collection (SDC) in rectal cancer: a prospective uniform naming and procedure convention to support personalized medicine. Radiother. Oncol. 112 (2014), 59–62.
29. [29] Collins, G., Reitsma, J., Altman, D., Moons, K., Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Ann. Intern. Med. 162 (2015), 55–63.
30. [30] De Ruysscher, D., Dehing, C., Yu, S., Wanders, R., Ollers, M., Dingemans, A., Bootsma, G., Hochstenbag, M., Geraedts, W., Pitz, C., Simons, J., Boersma, L., Borger, J., Dekker, A., Lambin, P., Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer. Radiother. Oncol., 2009.
31. [31] De Ruysscher, D., Houben, A., Aerts, H., Dehing, C., Wanders, R., Ollers, M., Dingemans, A., Hochstenbag, M., Boersma, L., Borger, J., Dekker, A., L. P., Increased (18)F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): a prospective pilot study. Radiother. Oncol. 91 (2009), 415–420.
32. [32] Steyerberg, E., Vickers, A., Cook, N., Gerds, T., Gonen, M., Obuchowski, N., Pencina, M., Kattan, M., Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 21 (2010), 128–138.
33. [33] Valentini, V., van Stiphout, R., Lammering, G., Gambacorta, M., Barba, M., Bebenek, M., Bonnetain, F., Bosset, J., Bujko, K., Cionini, L., Gerard, J., Rödel, C., Sainato, A., Sauer, R., Minsky, B., Collette, L., L. P., Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J. Clin. Oncol. 29 (2011), 3163–3172.
34. [34] Lambin, P., Zindler, J., Vanneste, B., Voorde, L. van de, Jacobs, M., Eekers, D., Peerlings, J., Reymen, B., Larue, R., Deist, T., Jong, E. de, Even, A., Berlanga, A., Roelofs, E., Cheng, Q., Carvalho, S., Leijenaar, R., Zegers, C., Limbergen, E. van, Berbee, M., Elmpt, W. van, Oberije, C., Houben, R., Dekker, A., Boersma, L., Verhaegen, F., Bosmans, G., Hoebers, F., Smits, K., Walsh, S., Modern clinical research: how rapid learning health care and cohort multiple randomised clinical trials complement traditional evidence based medicine. Acta. Oncol. 54 (2015), 1289–1300.
35. [35] Dekker, A.L., Gulliford, S.L., Ebert, M.A., Orton, C.G., Point/Counterpoint. Future radiotherapy practice will be based on evidence from retrospective interrogation of linked clinical data sources rather than prospective randomized controlled clinical trials. Med. Phys., 41, 2014, 030601.
36. [36] Grand, M.M., O'Brien, P.C., Obstacles to participation in randomised cancer clinical trials: a systematic review of the literature. J. Med. Imaging Radiat. Oncol. 56 (2012), 31–39.
37. [37] Murthy, V.H., Krumholz, H.M., Gross, C.P., Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291 (2004), 2720–2726.
38. [38] Dehing-Oberije, C., De Ruysscher, D., van Baardwijk, A., Yu, S., Rao, B., Lambin, P., The importance of patient characteristics for the prediction of radiation-induced lung toxicity. Radiother. Oncol. 91 (2009), 421–426.
39. [39] Oberije, C., De Ruysscher, D., Houben, R., van de Heuvel, M., Uyterlinde, W., Deasy, J., Belderbos, J., Dingemans, A., Rimner, A., Din, S., Lambin, P., A validated prediction model for overall survival from stage iii non-small cell lung cancer: toward survival prediction for individual patients. Int. J. Radiat. Oncol. Biol. Phys. 92 (2015), 935–944.
40. [40] Stacey, D., Bennett, C., Barry, M., Col, N., Eden, K., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Légaré, F., Thomson, R., Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst. Rev., 5, 2011.
41. [41] Li, J., Wang, M., Won, M., Shaw, E.G., Coughlin, C., Curran, W.J. Jr., Mehta, M.P., Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int. J. Radiat. Oncol. Biol. Phys. 81 (2011), 623–630.
42. [42] Michalski, J.M., Gay, H., Jackson, A., Tucker, S.L., Deasy, J.O., Radiation dose volume effects in radiation induced rectal injury. Int. J. Radiat. Oncol. Biol. Phys. 76 (2010), S123–S129.
43. [43] Walsh, S., van der Putten, W., A TCP model for external beam treatment of intermediate-risk prostate cancer. Med. Phys., 40, 2013, 11.
44. [44] Dekker, A., Vinod, S., Holloway, L., Oberije, C., George, A., Goozee, G., Delaney, G., Lambin, P., Thwaites, D., Rapid learning in practice: a lung cancer survival decision support system in routine patient care data. Radiother. Oncol., 113, 2014, 7.
45. [45] Dehing-Oberije, C., De Ruysscher, D., Petit, S., Van Meerbeeck, J., Vandecasteele, K., De Neve, W., Dingemans, A.M., El Naqa, I., Deasy, J., Bradley, J., Huang, E., Lambin, P., Development, external validation and clinical usefulness of a practical prediction model for radiation-induced dysphagia in lung cancer patients. Radiother. Oncol. 97 (2010), 455–461.
46. [46] Dehing-Oberije, C., Aerts, H., Yu, S., De Ruysscher, D., Menheere, P., Hilvo, M., van der Weide, H., Rao, B., Lambin, P., Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int. J. Radiat. Oncol. Biol. Phys. 81 (2011), 360–368.
47. [47] Bright, T.J., Wong, A., Dhurjati, R., Bristow, E., Bastian, L., Coeytaux, R.R., Samsa, G., Hasselblad, V., Williams, J.W., Musty, M.D., Wing, L., Kendrick, A.S., Sanders, G.D., Lobach, D., Effect of clinical decision-support systems: a systematic review. Ann. Intern. Med. 157 (2012), 29–43.
48. [48] Ramaekers, B.L., Grutters, J.P., Pijls-Johannesma, M., Lambin, P., Joore, M.A., Langendijk, J.A., Protons in head-and-neck cancer: bridging the gap of evidence. Int. J. Radiat. Oncol. Biol. Phys. 85 (2013), 1282–1288.
49. [49] Clark, G.M., Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib. Mol. Oncol. 1 (2008), 406–412.
50. [50] Dancey, J.E., Dobbin, K.K., Groshen, S., Jessup, J.M., Hruszkewycz, A.H., Koehler, M., Parchment, R., Ratain, M.J., Shankar, L.K., Stadler, W.M., True, L.D., Gravell, A., Grever, M.R., Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin. Cancer Res. 16 (2010), 1745–1755.
51. [51] Sesen, M.B., Nicholson, A.E., Banares-Alcantara, R., Kadir, T., Brady, M., Bayesian networks for clinical decision support in lung cancer care. PLoS One, 8, 2013, e82349.
52. [52] Peek, N., Arts, D.G., Bosman, R.J., van der Voort, P.H., de Keizer, N.F., External validation of prognostic models for critically ill patients required substantial sample sizes. J. Clin. Epidemiol. 60 (2007), 491–501.
53. [53] Vergouwe, Y., Steyerberg, E.W., Eijkemans, M.J., Habbema, J.D., Substantial effective sample sizes were required for external validation studies of predictive logistic regression models. J. Clin. Epidemiol. 58 (2005), 475–483.
54. [54] Aittokallio, T., Dealing with missing values in large-scale studies: microarray data imputation and beyond. Brief. Bioinform. 11 (2010), 253–264.
55. [55] Ludbrook, J., Outlying observations and missing values: how should they be handled?. Clin. Exp. Pharmacol. Physiol. 35 (2008), 670–678.
56. [56] Jayalakshmi, T., Santhakumaran, A., Statistical normalization and back propagation for classification. Int. J. Comput. Theory. Eng. 3 (2011), 89–93.
57. [57] Babyak, M.A., What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom. Med. 66 (2004), 411–421.
58. [58] Harrell, F.E. Jr., Lee, K.L., Califf, R.M., Pryor, D.B., Rosati, R.A., Regression modelling strategies for improved prognostic prediction. Stat. Med. 3 (1984), 143–152.
59. [59] Peduzzi, P., Concato, J., Kemper, E., Holford, T.R., Feinstein, A.R., A simulation study of the number of events per variable in logistic regression analysis. J. Clin. Epidemiol. 49 (1996), 1373–1379.
60. [60] Huan, L., Motoda, H., Feature Selection for Knowledge Discovery and Data Mining. 1998, Kluwer Academic Publishers, Norwell, MA.
61. [61] Harrell, F., Regression Modeling Strategies. 2011, Springer, New York.
62. [62] Bishop, C., Pattern Recognition and Machine Learning. 2007, Springer, N. Y.
63. [63] Kourou, K., Exarchos, T.P., Exarchos, K.P., Karamouzis, M.V., Fotiadis, D.I., Machine learning applications in cancer prognosis and prediction. Comput. Struct. Biotechnol. J. 13 (2015), 8–17.
64. [64] Lee, S.M., Abbott, P.A., Bayesian networks for knowledge discovery in large datasets: basics for nurse researchers. J. Biomed. Inform. 36 (2003), 389–399.
65. [65] Putter, H., Fiocco, M., Geskus, R.B., Tutorial in biostatistics: competing risks and multi-state models. Stat. Med. 26 (2007), 2389–2430.
66. [66] Akaike, H., A new look at the statistical model indentification. IEEE Trans. Autom. Control 19 (1974), 716–723.
67. [67] Moons, K.G., Kengne, A.P., Grobbee, D.E., Royston, P., Vergouwe, Y., Altman, D.G., Woodward, M., Risk prediction models: II. External validation, model updating, and impact assessment. Heart 98 (2012), 691–698.
68. [68] Specht, M.C., Kattan, M.W., Gonen, M., Fey, J., Van Zee, K.J., Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram. Ann. Surg. Oncol. 12 (2005), 654–659.
69. [69] Dehing-Oberije, C., De Ruysscher, D., van der Weide, H., Hochstenbag, M., Bootsma, G., Geraedts, W., Pitz, C., Simons, J., Teule, J., Rahmy, A., Thimister, P., Steck, H., Lambin, P., Tumor volume combined with number of positive lymph node stations is a more important prognostic factor than TNM stage for survival of non-small-cell lung cancer patients treated with (chemo)radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 70 (2008), 1039–1044.
70. [70] Vickers, A.J., Kramer, B.S., Baker, S.G., Selecting patients for randomized trials: a systematic approach based on risk group. Trials, 7, 2006, 30.
71. [71] Baggerly, K.A., Coombes, K.R., What information should be required to support clinical “omics” publications?. Clin. Chem. 57 (2011), 688–690.
72. [72] Klopp, A.H., Eifel, P.J., Biological predictors of cervical cancer response to radiation therapy. Semin. Radiat. Oncol. 22 (2012), 143–150.
73. [73] Kristiansen, G., Diagnostic and prognostic molecular biomarkers for prostate cancer. Histopathology 60 (2012), 125–141.
74. [74] Ang, C.S., Phung, J., Nice, E.C., The discovery and validation of colorectal cancer biomarkers. Biomed. Chromatogr. 25 (2011), 82–99.
75. [75] Schmidt, M.E., Steindorf, K., Statistical methods for the validation of questionnaires—discrepancy between theory and practice. Methods Inf. Med. 45 (2006), 409–413.
76. [76] Garrido-Laguna, I., Janku, F., Vaklavas, C., Falchook, G.S., Fu, S., Hong, D.S., Naing, A., Tsimberidou, A.M., Wen, S., Kurzrock, R., Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer 118 (2012), 1422–1428.
77. [77] Shrier, I., Boivin, J.F., Steele, R.J., Platt, R.W., Furlan, A., Kakuma, R., Brophy, J., Rossignol, M., Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. Am. J. Epidemiol. 166 (2007), 1203–1209.
78. [78] Tzoulaki, I., Siontis, K.C., Ioannidis, J.P., Prognostic effect size of cardiovascular biomarkers in datasets from observational studies versus randomised trials: meta-epidemiology study. BMJ, 343, 2011, d6829.
79. [79] N.C. Institute, N. NCI, DHHS, (eds.) Common Terminology Criteria for Adverse Events v4.0, 2009, National Cancer Institute.
80. [80] Trotti, A., Colevas, A.D., Setser, A., Basch, E., Patient-reported outcomes and the evolution of adverse event reporting in oncology. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 25 (2007), 5121–5127.
81. [81] Trotti, A., Colevas, A.D., Setser, A., Rusch, V., Jaques, D., Budach, V., Langer, C., Murphy, B., Cumberlin, R., Coleman, C.N., Rubin, P., CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin. Radiat. Oncol. 13 (2003), 176–181.
82. [82] Golder, S., Loke, Y.K., Bland, M., Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLoS Med., 8, 2011, e1001026.
83. [83] Steg, P.G., Lopez-Sendon, J., Lopez de Sa, E., Goodman, S.G., Gore, J.M., Anderson, F.A. Jr., Himbert, D., Allegrone, J., Van de Werf, F., External validity of clinical trials in acute myocardial infarction. Arch. Intern. Med. 167 (2007), 68–73.
84. [84] Little, J., Higgins, J.P., Ioannidis, J.P., Moher, D., Gagnon, F., Elm, E.v., Khoury, M.J., Cohen, B., Davey-Smith, G., Grimshaw, J., Scheet, P., Gwinn, M., Williamson, R.E., Zou, G.Y., Hutchings, K., Johnson, C.Y., Tait, V., Wiens, M., Golding, J., Duijn, C.v., McLaughlin, J., Paterson, A., Wells, G., Fortier, I., Freedman, M., Zecevic, M., King, R., Infante-Rivard, C., Stewart, A., Birkett, N., STrengthening the REporting of Genetic Association studies (STREGA)—an extension of the STROBE statement. Eur. J. Clin. Investig. 39 (2009), 247–266.
85. [85] von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., Gotzsche, P.C., Vandenbroucke, J.P., Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335 (2007), 806–808.
86. [86] von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., Gotzsche, P.C., Vandenbroucke, J.P., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 370 (2007), 1453–1457.
87. [87] Dawson, L.A., Sharpe, M.B., Image-guided radiotherapy: rationale, benefits, and limitations. Lancet Oncol. 7 (2006), 848–858.
88. [88] Jackson, A., Marks, L.B., Bentzen, S.M., Eisbruch, A., Yorke, E.D., Ten Haken, R.K., Constine, L.S., Deasy, J.O., The lessons of QUANTEC: recommendations for reporting and gathering data on dose–volume dependencies of treatment outcome. Int. J. Radiat. Oncol. Biol. Phys. 76 (2010), S155–S160.
89. [89] Bentzen, S.M., Constine, L.S., Deasy, J.O., Eisbruch, A., Jackson, A., Marks, L.B., Ten Haken, R.K., Yorke, E.D., Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int. J. Radiat. Oncol. Biol. Phys. 76 (2010), S3–S9.
90. [90] Jaffray, D.A., Lindsay, P.E., Brock, K.K., Deasy, J.O., Tomé, W.A., Accurate accumulation of dose for improved understanding of radiation effects in normal tissue. Int. J. Radiat. Oncol. Biol. Phys. 76 (2010), S135–S139.
91. [91] Jaffray, D.A., Image-guided radiotherapy: from current concept to future perspectives. Nat. Rev. Clin. Oncol. 9 (2012), 688–699.
92. [92] Hermans, B.C., Persoon, L.C., Podesta, M., Hoebers, F.J., Verhaegen, F., Troost, E.G., Weekly kilovoltage cone-beam computed tomography for detection of dose discrepancies during (chemo)radiotherapy for head and neck cancer. Acta Oncol. (Stockh.), 2015, 1–7.
93. [93] Belderbos, J., Uitterhoeve, L., van Zandwijk, N., Belderbos, H., Rodrigus, P., van de Vaart, P., Price, A., van Walree, N., Legrand, C., Dussenne, S., Bartelink, H., Giaccone, G., Koning, C., Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973). Eur. J. Cancer 43 (2007), 114–121.
94. [94] Lambin, P., Petit, S.F., Aerts, H.J., van Elmpt, W.J., Oberije, C.J., Starmans, M.H., van Stiphout, R.G., van Dongen, G.A., Muylle, K., Flamen, P., Dekker, A.L., De Ruysscher, D., The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non-small cell lung cancer. Radiother. Oncol. 96 (2010), 145–152.
95. [95] Bentzen, S., Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol. 6 (2005), 112–117.
96. [96] Emami, B., Lyman, J., Brown, A., Coia, L., Goitein, M., Munzenrider, J.E., Shank, B., Solin, L.J., Wesson, M., Tolerance of normal tissue to therapeutic irradiation. Int. J. Radiat. Oncol. Biol. Phys. 21 (1991), 109–122.
97. [97] Marks, L.B., Bentzen, S.M., Deasy, J.O., Kong, F.M., Bradley, J.D., Vogelius, I.S., El Naqa, I., Hubbs, J.L., Lebesque, J.V., Timmerman, R.D., Martel, M.K., Jackson, A., Radiation dose–volume effects in the lung. Int. J. Radiat. Oncol. Biol. Phys. 76 (2010), S70–S76.
98. [98] Werner-Wasik, M., Yorke, E., Deasy, J., Nam, J., Marks, L.B., Radiation dose–volume effects in the esophagus. Int. J. Radiat. Oncol. Biol. Phys. 76 (2010), S86–S93.
99. [99] Schultheiss, T.E., The radiation dose–response of the human spinal cord. Int. J. Radiat. Oncol. Biol. Phys. 71 (2008), 1455–1459.
100. [100] Beetz, I., Schilstra, C., Schaaf, A.v.d., Heuvel, E.R.v.d., Doornaert, P., Luijk, P.v., Vissink, A., Laan, B.F.v.d., Leemans, C.R., Bijl, H.P., Christianen, M.E., Steenbakkers, R.J., Langendijk, J.A., NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: the role of dosimetric and clinical factors. Radiother. Oncol. 105 (2012), 101–106.
101. [101] Beetz, I., Schilstra, C., van Luijk, P., Christianen, M.E., Doornaert, P., Bijl, H.P., Chouvalova, O., van den Heuvel, E.R., Steenbakkers, R.J., Langendijk, J.A., External validation of three dimensional conformal radiotherapy based NTCP models for patient-rated xerostomia and sticky saliva among patients treated with intensity modulated radiotherapy. Radiother. Oncol. 105 (2012), 94–100.
102. [102] Boomsma, M.J., Bijl, H.P., Christianen, M.E., Beetz, I., Chouvalova, O., Steenbakkers, R.J., van der Laan, B.F., Wolffenbuttel, B.H., Oosting, S.F., Schilstra, C., Langendijk, J.A., A prospective cohort study on radiation-induced hypothyroidism: development of an NTCP model. Int. J. Radiat. Oncol. Biol. Phys. 84 (2012), e351–e356.
103. [103] Christianen, M.E., Verdonck-de Leeuw, I.M., Doornaert, P., Chouvalova, O., Steenbakkers, R.J., Koken, P.W., Rene Leemans, C., Oosting, S.F., Roodenburg, J.L., van der Laan, B.F., Slotman, B.J., Bijl, H.P., Langendijk, J.A., Patterns of long-term swallowing dysfunction after definitive radiotherapy or chemoradiation. Radiother. Oncol., 2015.
104. [104] Ramaekers, B.L., Joore, M.A., Grutters, J.P., van den Ende, P., Jong, J., Houben, R., Lambin, P., Christianen, M., Beetz, I., Pijls-Johannesma, M., Langendijk, J.A., The impact of late treatment-toxicity on generic health-related quality of life in head and neck cancer patients after radiotherapy. Oral Oncol. 47 (2011), 768–774.
105. [105] Wopken, K., Bijl, H.P., van der Schaaf, A., Christianen, M.E., Chouvalova, O., Oosting, S.F., van der Laan, B.F., Roodenburg, J.L., Leemans, C.R., Slotman, B.J., Doornaert, P., Steenbakkers, R.J., Verdonck-de Leeuw, I.M., Langendijk, J.A., Development and validation of a prediction model for tube feeding dependence after curative (chemo-) radiation in head and neck cancer. PLoS One, 9, 2014, e94879.
106. [106] van der Schaaf, A., Xu, C.J., van Luijk, P., Van't Veld, A.A., Langendijk, J.A., Schilstra, C., Multivariate modeling of complications with data driven variable selection: guarding against overfitting and effects of data set size. Radiother. Oncol. 105 (2012), 115–121.
107. [107] Xu, C.J., van der Schaaf, A., Van't Veld, A.A., Langendijk, J.A., Schilstra, C., Statistical validation of normal tissue complication probability models. Int. J. Radiat. Oncol. Biol. Phys. 84 (2012), e123–e129.
108. [108] Podesta, M., Nijsten, S.M., Persoon, L.C., Scheib, S.G., Baltes, C., Verhaegen, F., Time dependent pre-treatment EPID dosimetry for standard and FFF VMAT. Phys. Med. Biol. 59 (2014), 4749–4768.
109. [109] Nijsten, S.M., Mijnheer, B.J., Dekker, A.L., Lambin, P., Minken, A.W., Routine individualised patient dosimetry using electronic portal imaging devices. Radiother. Oncol. 83 (2007), 65–75.
110. [110] Podesta, M., Persoon, L.C., Verhaegen, F., A novel time dependent gamma evaluation function for dynamic 2D and 3D dose distributions. Phys. Med. Biol. 59 (2014), 5973–5985.
111. [111] van Elmpt, W., Nijsten, S., Petit, S., Mijnheer, B., Lambin, P., Dekker, A., 3D in vivo dosimetry using megavoltage cone-beam CT and EPID dosimetry. Int. J. Radiat. Oncol. Biol. Phys. 73 (2009), 1580–1587.
112. [112] van Elmpt, W., Petit, S., De Ruysscher, D., Lambin, P., Dekker, A., 3D dose delivery verification using repeated cone-beam imaging and EPID dosimetry for stereotactic body radiotherapy of non-small cell lung cancer. Radiother. Oncol. 94 (2010), 188–194.
113. [113] Rodrigues, G., Lock, M., D'Souza, D., Yu, E., Van Dyk, J., Prediction of radiation pneumonitis by dose–volume histogram parameters in lung cancer—a systematic review. Radiother. Oncol. 71 (2004), 127–138.
114. [114] Jones, B., Dale, R.G., Deehan, C., Hopkins, K.I., Morgan, D.A., The role of biologically effective dose (BED) in clinical oncology. Clin. Oncol. (R. Coll. Radiol.) 13 (2001), 71–81.
115. [115] Fowler, J.F., 21 years of biologically effective dose. Br. J. Radiol. 83 (2010), 554–568.
116. [116] Fowler, J.F., The linear–quadratic formula and progress in fractionated radiotherapy. Br. J. Radiol. 62 (1989), 679–694.
117. [117] Saunders, M., Rojas, A.M., Dische, S., CHART revisited: a conservative approach for advanced head and neck cancer. Clin. Oncol. (R. Coll. Radiol.) 20 (2008), 127–133.
118. [118] Turner, N., Lambros, M.B., Horlings, H.M., Pearson, A., Sharpe, R., Natrajan, R., Geyer, F.C., van Kouwenhove, M., Kreike, B., Mackay, A., Ashworth, A., van de Vijver, M.J., Reis-Filho, J.S., Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29 (2010), 2013–2023.
119. [119] Begg, A.C., Haustermans, K., Hart, A.A., Dische, S., Saunders, M., Zackrisson, B., Gustaffson, H., Coucke, P., Paschoud, N., Hoyer, M., Overgaard, J., Antognoni, P., Richetti, A., Bourhis, J., Bartelink, H., Horiot, J.C., Corvo, R., Giaretti, W., Awwad, H., Shouman, T., Jouffroy, T., Maciorowski, Z., Dobrowsky, W., Struikmans, H., Wilson, G.D., et al. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: a multicenter analysis. Radiother. Oncol. 50 (1999), 13–23.
120. [120] Huang, Z., Mayr, N.A., Gao, M., Lo, S.S., Wang, J.Z., Jia, G., Yuh, W.T.C., The onset time of tumor repopulation for cervical cancer — first evidence from clinical data. Int. J. Radiat. Oncol. Biol. Phys. 84 (2012), 478–484.
121. [121] Baumann, M., Krause, M., Hill, R., Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer 8 (2008), 545–554.
122. [122] Hessel, F., Petersen, C., Zips, D., Krause, M., Pfitzmann, D., Thames, H.D., Baumann, M., Impact of increased cell loss on the repopulation rate during fractionated irradiation in human FaDu squamous cell carcinoma growing in nude mice. Int. J. Radiat. Biol. 79 (2003), 479–486.
123. [123] Ben-Josef, E., Moughan, J., Ajani, J.A., Flam, M., Gunderson, L., Pollock, J., Myerson, R., Anne, R., Rosenthal, S.A., Willett, C., Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 28 (2010), 5061–5066.
124. [124] Song, S., Rudra, S., Hasselle, M.D., Dorn, P.L., Mell, L.K., Mundt, A.J., Yamada, S.D., Lee, N.K., Hasan, Y., The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy. Cancer 119 (2013), 325–331.
125. [125] Thames, H.D., Kuban, D., Levy, L.B., Horwitz, E.M., Kupelian, P., Martinez, A., Michalski, J., Pisansky, T., Sandler, H., Shipley, W., Zelefsky, M., Zietman, A., The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother. Oncol. 96 (2010), 6–12.
126. [126] Petit, S.F., Aerts, H.J., van Loon, J.G., Offermann, C., Houben, R., Winkens, B., Ollers, M.C., Lambin, P., De Ruysscher, D., Dekker, A.L., Metabolic control probability in tumour subvolumes or how to guide tumour dose redistribution in non-small cell lung cancer (NSCLC): an exploratory clinical study. Radiother. Oncol. 91 (2009), 393–398.
127. [127] Petit, S.F., van Elmpt, W.J., Oberije, C.J., Vegt, E., Dingemans, A.M., Lambin, P., Dekker, A.L., De Ruysscher, D., [(1)(8)F]fluorodeoxyglucose uptake patterns in lung before radiotherapy identify areas more susceptible to radiation-induced lung toxicity in non-small-cell lung cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 81 (2011), 698–705.
128. [128] Fass, L., Imaging and cancer: a review. Mol. Oncol. 2 (2008), 115–152.
129. [129] Torigian, D.A., Huang, S.S., Houseni, M., Alavi, A., Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J. Clin. 57 (2007), 206–224.
130. [130] Eadie, L.H., Taylor, P., Gibson, A.P., A systematic review of computer-assisted diagnosis in diagnostic cancer imaging. Eur. J. Radiol. 81 (2012), e70–e76.
131. [131] Gillies, R.J., Anderson, A.R., Gatenby, R.A., Morse, D.L., The biology underlying molecular imaging in oncology: from genome to anatome and back again. Clin. Radiol. 65 (2010), 517–521.
132. [132] Caldwell, C.B., Mah, K., Ung, Y.C., Danjoux, C.E., Balogh, J.M., Ganguli, S.N., Ehrlich, L.E., Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. Int. J. Radiat. Oncol. Biol. Phys. 51 (2001), 923–931.
133. [133] Cangir, A.K., Kutlay, H., Akal, M., Gungor, A., Ozdemir, N., Akay, H., Prognostic value of tumor size in non-small cell lung cancer larger than five centimeters in diameter, Lung Cancer 46 (2004), 325–331.
134. [134] Greco, C., Rosenzweig, K., Cascini, G.L., Tamburrini, O., Current status of PET/CT for tumour volume definition in radiotherapy treatment planning for non-small cell lung cancer (NSCLC). Lung Cancer 57 (2007), 125–134.
135. [135] Lam, J.S., Klatte, T., Patard, J.J., Goel, R.H., Guille, F., Lobel, B., Abbou, C.C., De La Taille, A., Tostain, J., Cindolo, L., Altieri, V., Ficarra, V., Artibani, W., Prayer-Galetti, T., Schips, L., Zigeuner, R., Pantuck, A.J., Figlin, R.A., Belldegrun, A.S., Prognostic relevance of tumour size in T3a renal cell carcinoma: a multicentre experience. Eur. Urol. 52 (2007), 155–162.
136. [136] Pitson, G., Fyles, A., Milosevic, M., Wylie, J., Pintilie, M., Hill, R., Tumor size and oxygenation are independent predictors of nodal diseases in patients with cervix cancer. Int. J. Radiat. Oncol. Biol. Phys. 51 (2001), 699–703.
137. [137] Steenbakkers, R.J., Duppen, J.C., Fitton, I., Deurloo, K.E., Zijp, L., Uitterhoeve, A.L., Rodrigus, P.T., Kramer, G.W., Bussink, J., De Jaeger, K., Belderbos, J.S., Hart, A.A., Nowak, P.J., van Herk, M., Rasch, C.R., Observer variation in target volume delineation of lung cancer related to radiation oncologist-computer interaction: a ‘Big Brother’ evaluation. Radiother. Oncol. 77 (2005), 182–190.
138. [138] Thomas, F., Arriagada, R., Mouriesse, H., Sillet-Bach, I., Kunkler, I., Fontaine, F., Le Chevalier, T., Contesso, G., Sarrazin, D., Radical radiotherapy alone in non-operable breast cancer: the major impact of tumor size and histological grade on prognosis. Radiother. Oncol. 13 (1988), 267–276.
139. [139] Velazquez, E.R., Aerts, H.J., Oberije, C., De Ruysscher, D., Lambin, P., Prediction of residual metabolic activity after treatment in NSCLC patients. Acta Oncol. (Stockh.) 49 (2010), 1033–1039.
140. [140] Bowden, P., Fisher, R., Mac Manus, M., Wirth, A., Duchesne, G., Millward, M., McKenzie, A., Andrews, J., Ball, D., Measurement of lung tumor volumes using three-dimensional computer planning software. Int. J. Radiat. Oncol. Biol. Phys. 53 (2002), 566–573.
141. [141] Marcus, C.D., Ladam-Marcus, V., Cucu, C., Bouche, O., Lucas, L., Hoeffel, C., Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit. Rev. Oncol. Hematol. 72 (2009), 217–238.
142. [142] Nishino, M., Guo, M., Jackman, D.M., DiPiro, P.J., Yap, J.T., Ho, T.K., Hatabu, H., Janne, P.A., Van den Abbeele, A.D., Johnson, B.E., CT tumor volume measurement in advanced non-small-cell lung cancer: performance characteristics of an emerging clinical tool. Acad. Radiol. 18 (2011), 54–62.
143. [143] Erasmus, J.J., Gladish, G.W., Broemeling, L., Sabloff, B.S., Truong, M.T., Herbst, R.S., Munden, R.F., Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 21 (2003), 2574–2582.
144. [144] Schwartz, L.H., Mazumdar, M., Brown, W., Smith, A., Panicek, D.M., Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. Clin. Cancer Res. 9 (2003), 4318–4323.
145. [145] Therasse, P., Measuring the clinical response. What does it mean?. Eur. J. Cancer 38 (2002), 1817–1823.
146. [146] Desar, I.M., van Herpen, C.M., van Laarhoven, H.W., Barentsz, J.O., Oyen, W.J., van der Graaf, W.T., Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat. Rev. 35 (2009), 309–321.
147. [147] Moertel, C.G., Hanley, J.A., The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 38 (1976), 388–394.
148. [148] Wahl, R.L., Jacene, H., Kasamon, Y., Lodge, M.A., From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50:Suppl. 1 (2009), 122S–150S.
149. [149] Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O., Lammertsma, A.A., Pruim, J., Price, P., Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur. J. Cancer 35 (1999), 1773–1782.
150. [150] Nehmeh, S.A., Erdi, Y.E., Respiratory motion in positron emission tomography/computed tomography: a review. Semin. Nucl. Med. 38 (2008), 167–176.
151. [151] Sonke, J.J., Belderbos, J., Adaptive radiotherapy for lung cancer. Semin. Radiat. Oncol. 20 (2010), 94–106.
152. [152] Strassmann, G., Abdellaoui, S., Richter, D., Bekkaoui, F., Haderlein, M., Fokas, E., Timmesfeld, N., Vogel, B., Henzel, M., Engenhart-Cabillic, R., Atlas-based semiautomatic target volume definition (CTV) for head-and-neck tumors. Int. J. Radiat. Oncol. Biol. Phys. 78 (2010), 1270–1276.
153. [153] van Baardwijk, A., Bosmans, G., Boersma, L., Buijsen, J., Wanders, S., Hochstenbag, M., van Suylen, R.J., Dekker, A., Dehing-Oberije, C., Houben, R., Bentzen, S.M., van Kroonenburgh, M., Lambin, P., De Ruysscher, D., PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int. J. Radiat. Oncol. Biol. Phys. 68 (2007), 771–778.
154. [154] Wanet, M., Lee, J.A., Weynand, B., De Bast, M., Poncelet, A., Lacroix, V., Coche, E., Gregoire, V., Geets, X., Gradient-based delineation of the primary GTV on FDG-PET in non-small cell lung cancer: a comparison with threshold-based approaches, CT and surgical specimens. Radiother. Oncol. 98 (2011), 117–125.
155. [155] Wu, K., Ung, Y.C., Hornby, J., Freeman, M., Hwang, D., Tsao, M.S., Dahele, M., Darling, G., Maziak, D.E., Tirona, R., Mah, K., Wong, C.S., PET CT thresholds for radiotherapy target definition in non-small-cell lung cancer: how close are we to the pathologic findings?. Int. J. Radiat. Oncol. Biol. Phys. 77 (2010), 699–706.
156. [156] Daisne, J.F., Duprez, T., Weynand, B., Lonneux, M., Hamoir, M., Reychler, H., Gregoire, V., Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 233 (2004), 93–100.
157. [157] Nestle, U., Kremp, S., Schaefer-Schuler, A., Sebastian-Welsch, C., Hellwig, D., Rube, C., Kirsch, C.M., Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J. Nucl. Med. 46 (2005), 1342–1348.
158. [158] van Loon, J., van Baardwijk, A., Boersma, L., Ollers, M., Lambin, P., De Ruysscher, D., Therapeutic implications of molecular imaging with PET in the combined modality treatment of lung cancer. Cancer Treat. Rev. 37 (2011), 331–343.
159. [159] O'Connor, J.P., Jackson, A., Asselin, M.C., Buckley, D.L., Parker, G.J., Jayson, G.C., Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. Lancet Oncol. 9 (2008), 766–776.
160. [160] Wood, K.A., Hoskin, P.J., Saunders, M.I., Positron emission tomography in oncology: a review. Clin. Oncol. (R. Coll. Radiol.) 19 (2007), 237–255.
161. [161] Borst, G.R., Belderbos, J.S., Boellaard, R., Comans, E.F., De Jaeger, K., Lammertsma, A.A., Lebesque, J.V., Standardised FDG uptake: a prognostic factor for inoperable non-small cell lung cancer. Eur. J. Cancer 41 (2005), 1533–1541.
162. [162] Chung, H.H., Kim, J.W., Han, K.H., Eo, J.S., Kang, K.W., Park, N.H., Song, Y.S., Chung, J.K., Kang, S.B., Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. Gynecol. Oncol. 120 (2011), 270–274.
163. [163] Differding, S., Hanin, F.X., Gregoire, V., PET imaging biomarkers in head and neck cancer. Eur. J. Nucl. Med. Mol. Imaging 42 (2015), 613–622.
164. [164] Hoekstra, C.J., Stroobants, S.G., Smit, E.F., Vansteenkiste, J., van Tinteren, H., Postmus, P.E., Golding, R.P., Biesma, B., Schramel, F.J., van Zandwijk, N., Lammertsma, A.A., Hoekstra, O.S., Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 23 (2005), 8362–8370.
165. [165] Mac Manus, M.P., Hicks, R.J., Matthews, J.P., Wirth, A., Rischin, D., Ball, D.L., Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure. Lung Cancer 49 (2005), 95–108.
166. [166] Soto, D.E., Kessler, M.L., Piert, M., Eisbruch, A., Correlation between pretreatment FDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers. Radiother. Oncol. 89 (2008), 13–18.
167. [167] van Baardwijk, A., Bosmans, G., Dekker, A., van Kroonenburgh, M., Boersma, L., Wanders, S., Ollers, M., Houben, R., Minken, A., Lambin, P., De Ruysscher, D., Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients. Radiother. Oncol. 82 (2007), 145–152.
168. [168] Ceulemans, G., Voordeckers, M., Farrag, A., Verdries, D., Storme, G., Everaert, H., Can 18-FDG–PET during radiotherapy replace post-therapy scanning for detection/demonstration of tumor response in head-and-neck cancer?. Int. J. Radiat. Oncol. Biol. Phys. 81 (2011), 938–942.
169. [169] Janssen, M.H., Ollers, M.C., van Stiphout, R.G., Buijsen, J., van den Bogaard, J., de Ruysscher, D., Lambin, P., Lammering, G., Evaluation of early metabolic responses in rectal cancer during combined radiochemotherapy or radiotherapy alone: sequential FDG–PET-CT findings. Radiother. Oncol. 94 (2010), 151–155.
170. [170] Lambrecht, M., Deroose, C., Roels, S., Vandecaveye, V., Penninckx, F., Sagaert, X., van Cutsem, E., de Keyzer, F., Haustermans, K., The use of FDG–PET/CT and diffusion-weighted magnetic resonance imaging for response prediction before, during and after preoperative chemoradiotherapy for rectal cancer. Acta Oncol. (Stockh.) 49 (2010), 956–963.
171. [171] van Loon, J., Offermann, C., Ollers, M., van Elmpt, W., Vegt, E., Rahmy, A., Dingemans, A.M., Lambin, P., De Ruysscher, D., Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study. Radiother. Oncol. 99 (2011), 172–175.
172. [172] Boellaard, R., Need for standardization of 18F-FDG PET/CT for treatment response assessments. J. Nucl. Med. 52:Suppl. 2 (2011), 93S–100S.
173. [173] Bussink, J., Kaanders, J.H., van der Graaf, W.T., Oyen, W.J., PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat. Rev. Clin. Oncol. 8 (2011), 233–242.
174. [174] Boellaard, R., O'Doherty, M.J., Weber, W.A., Mottaghy, F.M., Lonsdale, M.N., Stroobants, S.G., Oyen, W.J., Kotzerke, J., Hoekstra, O.S., Pruim, J., Marsden, P.K., Tatsch, K., Hoekstra, C.J., Visser, E.P., Arends, B., Verzijlbergen, F.J., Zijlstra, J.M., Comans, E.F., Lammertsma, A.A., Paans, A.M., Willemsen, A.T., Beyer, T., Bockisch, A., Schaefer-Prokop, C., Delbeke, D., Baum, R.P., Chiti, A., Krause, B.J., FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur. J. Nucl. Med. Mol. Imaging 37 (2010), 181–200.
175. [175] Peeters, S.G., Zegers, C.M., Lieuwes, N.G., van Elmpt, W., Eriksson, J., van Dongen, G.A., Dubois, L., Lambin, P., A comparative study of the hypoxia PET tracers [(1)(8)F]HX4, [(1)(8)F]FAZA, and [(1)(8)F]FMISO in a preclinical tumor model. Int. J. Radiat. Oncol. Biol. Phys. 91 (2015), 351–359.
176. [176] van Loon, J., Janssen, M.H., Ollers, M., Aerts, H.J., Dubois, L., Hochstenbag, M., Dingemans, A.M., Lalisang, R., Brans, B., Windhorst, B., van Dongen, G.A., Kolb, H., Zhang, J., De Ruysscher, D., Lambin, P., PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur. J. Nucl. Med. Mol. Imaging 37 (2010), 1663–1668.
177. [177] Zegers, C.M., van Elmpt, W., Reymen, B., Even, A.J., Troost, E.G., Ollers, M.C., Hoebers, F.J., Houben, R.M., Eriksson, J., Windhorst, A.D., Mottaghy, F.M., De Ruysscher, D., Lambin, P., In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging. Clin. Cancer Res. 20 (2014), 6389–6397.
178. [178] Boellaard, R., Oyen, W.J., Hoekstra, C.J., Hoekstra, O.S., Visser, E.P., Willemsen, A.T., Arends, B., Verzijlbergen, F.J., Zijlstra, J., Paans, A.M., Comans, E.F., Pruim, J., The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur. J. Nucl. Med. Mol. Imaging 35 (2008), 2320–2333.
179. [179] Bayouth, J.E., Casavant, T.L., Graham, M.M., Sonka, M., Muruganandham, M., Buatti, J.M., Image-based biomarkers in clinical practice. Semin. Radiat. Oncol. 21 (2011), 157–166.
180. [180] Harry, V.N., Semple, S.I., Parkin, D.E., Gilbert, F.J., Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol. 11 (2010), 92–102.
181. [181] Heijmen, L., Verstappen, M.C., Ter Voert, E.E., Punt, C.J., Oyen, W.J., de Geus-Oei, L.F., Hermans, J.J., Heerschap, A., van Laarhoven, H.W., Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use?. Crit. Rev. Oncol. Hematol. 83 (2012), 194–207.
182. [182] Vandecaveye, V., Dirix, P., De Keyzer, F., Op de Beeck, K., Vander Poorten, V., Hauben, E., Lambrecht, M., Nuyts, S., Hermans, R., Diffusion-weighted magnetic resonance imaging early after chemoradiotherapy to monitor treatment response in head-and-neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 82 (2012), 1098–1107.
183. [183] Kim, S.Y., Lee, S.S., Byun, J.H., Park, S.H., Kim, J.K., Park, B., Kim, N., Lee, M.G., Malignant hepatic tumors: short-term reproducibility of apparent diffusion coefficients with breath-hold and respiratory-triggered diffusion-weighted MR imaging. Radiology 255 (2010), 815–823.
184. [184] Kierkels, R.G., Backes, W.H., Janssen, M.H., Buijsen, J., Beets-Tan, R.G., Lambin, P., Lammering, G., Oellers, M.C., Aerts, H.J., Comparison between perfusion computed tomography and dynamic contrast-enhanced magnetic resonance imaging in rectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 77 (2010), 400–408.
185. [185] Shukla-Dave, A., Lee, N.Y., Jansen, J.F., Thaler, H.T., Stambuk, H.E., Fury, M.G., Patel, S.G., Moreira, A.L., Sherman, E., Karimi, S., Wang, Y., Kraus, D., Shah, J.P., Pfister, D.G., Koutcher, J.A., Dynamic contrast-enhanced magnetic resonance imaging as a predictor of outcome in head-and-neck squamous cell carcinoma patients with nodal metastases. Int. J. Radiat. Oncol. Biol. Phys. 82 (2012), 1837–1844.
186. [186] Sinkus, R., Van Beers, B.E., Vilgrain, V., DeSouza, N., Waterton, J.C., Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development. Eur. J. Cancer 48 (2012), 425–431.
187. [187] Morchel, P., Melkus, G., Yaromina, A., Zips, D., Baumann, M., Jakob, P.M., Flentje, M., Correlating quantitative MR measurements of standardized tumor lines with histological parameters and tumor control dose. Radiother. Oncol. 96 (2010), 123–130.
188. [188] Quennet, V., Yaromina, A., Zips, D., Rosner, A., Walenta, S., Baumann, M., Mueller-Klieser, W., Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother. Oncol. 81 (2006), 130–135.
189. [189] Yaromina, A., Quennet, V., Zips, D., Meyer, S., Shakirin, G., Walenta, S., Mueller-Klieser, W., Baumann, M., Co-localisation of hypoxia and perfusion markers with parameters of glucose metabolism in human squamous cell carcinoma (hSCC) xenografts. Int. J. Radiat. Biol. 85 (2009), 972–980.
190. [190] Kim, Y.I., Chung, J.W., Park, J.H., Kang, G.H., Lee, M., Suh, K.S., Kim, K.G., Multiphase contrast-enhanced CT imaging in hepatocellular carcinoma correlation with immunohistochemical angiogenic activities. Acad. Radiol. 14 (2007), 1084–1091.
191. [191] Miles, K.A., Perfusion CT for the assessment of tumour vascularity: which protocol?. Br. J. Radiol. 76:Spec No 1 (2003), S36–S42.
192. [192] van Elmpt, W., Zegers, C.M., Das, M., De Ruysscher, D., Imaging techniques for tumour delineation and heterogeneity quantification of lung cancer: overview of current possibilities. J. Thorac. Dis. 6 (2014), 319–327.
193. [193] Miles, K.A., Molecular imaging with dynamic contrast-enhanced computed tomography. Clin. Radiol. 65 (2010), 549–556.
194. [194] Petralia, G., Bonello, L., Viotti, S., Preda, L., d'Andrea, G., Bellomi, M., CT perfusion in oncology: how to do it. Cancer Imaging 10 (2010), 8–19.
195. [195] Asselin, M.C., O'Connor, J.P., Boellaard, R., Thacker, N.A., Jackson, A., Quantifying heterogeneity in human tumours using MRI and PET. Eur. J. Cancer 48 (2012), 447–455.
196. [196] Eary, J.F., O'Sullivan, F., O'Sullivan, J., Conrad, E.U., Spatial heterogeneity in sarcoma 18F-FDG uptake as a predictor of patient outcome. J. Nucl. Med. 49 (2008), 1973–1979.
197. [197] Tixier, F., Le Rest, C.C., Hatt, M., Albarghach, N., Pradier, O., Metges, J.P., Corcos, L., Visvikis, D., Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J. Nucl. Med. 52 (2011), 369–378.
198. [198] Pepperkok, R., Ellenberg, J., High-throughput fluorescence microscopy for systems biology. Nat. Rev. Mol. Cell Biol. 7 (2006), 690–696.
199. [199] Panth, K.M., Leijenaar, R.T., Carvalho, S., Lieuwes, N.G., Yaromina, A., Dubois, L., Lambin, P., Is there a causal relationship between genetic changes and radiomics-based image features? An in vivo preclinical experiment with doxycycline inducible GADD34 tumor cells. Radiother. Oncol., 2015.
200. [200] Gutman, D.A., Dunn, W.D. Jr., Grossmann, P., Cooper, L.A., Holder, C.A., Ligon, K.L., Alexander, B.M., Aerts, H.J., Somatic mutations associated with MRI-derived volumetric features in glioblastoma. Neuroradiology, 2015.
201. [201] Diehn, M., Nardini, C., Wang, D.S., McGovern, S., Jayaraman, M., Liang, Y., Aldape, K., Cha, S., Kuo, M.D., Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 5213–5218.
202. [202] Kuo, M.D., Gollub, J., Sirlin, C.B., Ooi, C., Chen, X., Radiogenomic analysis to identify imaging phenotypes associated with drug response gene expression programs in hepatocellular carcinoma. J. Vasc. Interv. Radiol. 18 (2007), 821–831.
203. [203] Segal, E., Sirlin, C.B., Ooi, C., Adler, A.S., Gollub, J., Chen, X., Chan, B.K., Matcuk, G.R., Barry, C.T., Chang, H.Y., Kuo, M.D., Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat. Biotechnol. 25 (2007), 675–680.
204. [204] Rutman, A.M., Kuo, M.D., Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur. J. Radiol. 70 (2009), 232–241.
205. [205] van Elmpt, W., Zegers, C.M., Reymen, B., Even, A.J., Dingemans, A.C., Oellers, M., Wildberger, J.E., Mottaghy, F.M., Das, M., Troost, E.G., Lambin, P., Multiparametric imaging of patient and tumour heterogeneity in non-small-cell lung cancer: quantification of tumour hypoxia, metabolism and perfusion. Eur. J. Nucl. Med. Mol. Imaging, 2015.
206. [206] Yankeelov, T.E., Abramson, R.G., Quarles, C.C., Quantitative multimodality imaging in cancer research and therapy. Nat. Rev. Clin. Oncol. 11 (2014), 670–680.
207. [207] Aerts, H., Rios-Velazquez, E., Leijenaar, R., Parmar, C., Grossmann, P., Carvalho, S., Bussink, J., Monshouwer, R., Haibe-Kains, B., Rietveld, D., Hoebers, F., Rietbergen, M., Leemans, C., Dekker, A., Quackenbush, J., Gillies, R., Lambin, P., Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat. Commun., 5, 2014.
208. [208] Fisher, R., Pusztai, L., Swanton, C., Cancer heterogeneity: implications for targeted therapeutics. Br. J. Cancer 108 (2013), 479–485.
209. [209] Longo, D.L., Tumor heterogeneity and personalized medicine. N. Engl. J. Med. 366 (2012), 956–957.
210. [210] Szerlip, N.J., Pedraza, A., Chakravarty, D., Azim, M., McGuire, J., Fang, Y., Ozawa, T., Holland, E.C., Huse, J.T., Jhanwar, S., Leversha, M.A., Mikkelsen, T., Brennan, C.W., Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 3041–3046.
211. [211] Ng, C.K., Pemberton, H.N., Reis-Filho, J.S., Breast cancer intratumor genetic heterogeneity: causes and implications. Expert. Rev. Anticancer. Ther. 12 (2012), 1021–1032.
212. [212] Collins, F.S., Varmus, H., A new initiative on precision medicine. N. Engl. J. Med. 372 (2015), 793–795.
213. [213] Cistaro, A., Quartuccio, N., Mojtahedi, A., Fania, P., Filosso, P.L., Campenni, A., Ficola, U., Baldari, S., Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing (18)F-FDG PET/CT SUV quantification. Radiol. Oncol. 47 (2013), 219–223.
214. [214] Cook, G.J., Yip, C., Siddique, M., Goh, V., Chicklore, S., Roy, A., Marsden, P., Ahmad, S., Landau, D., Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?. J. Nucl. Med. 54 (2013), 19–26.
215. [215] Coroller, T.P., Grossmann, P., Hou, Y., Rios Velazquez, E., Leijenaar, R.T., Hermann, G., Lambin, P., Haibe-Kains, B., Mak, R.H., Aerts, H.J., CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. Radiother. Oncol. 114 (2015), 345–350.
216. [216] Ganeshan, B., Goh, V., Mandeville, H.C., Ng, Q.S., Hoskin, P.J., Miles, K.A., Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. Radiology 266 (2013), 326–336.
217. [217] Gevaert, O., Xu, J., Hoang, C.D., Leung, A.N., Xu, Y., Quon, A., Rubin, D.L., Napel, S., Plevritis, S.K., Non-small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data–methods and preliminary results. Radiology 264 (2012), 387–396.
218. [218] Pickles, M.D., Manton, D.J., Lowry, M., Turnbull, L.W., Prognostic value of pre-treatment DCE-MRI parameters in predicting disease free and overall survival for breast cancer patients undergoing neoadjuvant chemotherapy. Eur. J. Radiol. 71 (2009), 498–505.
219. [219] Nicolasjilwan, M., Hu, Y., Yan, C., Meerzaman, D., Holder, C.A., Gutman, D., Jain, R., Colen, R., Rubin, D.L., Zinn, P.O., Hwang, S.N., Raghavan, P., Hammoud, D.A., Scarpace, L.M., Mikkelsen, T., Chen, J., Gevaert, O., Buetow, K., Freymann, J., Kirby, J., Flanders, A.E., Wintermark, M., Addition of MR imaging features and genetic biomarkers strengthens glioblastoma survival prediction in TCGA patients. J. Neuroradiol. 42 (2015), 212–221.
220. [220] Alic, L., Niessen, W.J., Veenland, J.F., Quantification of heterogeneity as a biomarker in tumor imaging: a systematic review. PLoS One, 9, 2014, e110300.
221. [221] Carvalho, S., Leijenaar, R.T., Velazquez, E.R., Oberije, C., Parmar, C., van Elmpt, W., Reymen, B., Troost, E.G., Oellers, M., Dekker, A., Gillies, R., Aerts, H.J., Lambin, P., Prognostic value of metabolic metrics extracted from baseline positron emission tomography images in non-small cell lung cancer. Acta Oncol. (Stockh.) 52 (2013), 1398–1404.
222. [222] Gevaert, O., Mitchell, L.A., Achrol, A.S., Xu, J., Echegaray, S., Steinberg, G.K., Cheshier, S.H., Napel, S., Zaharchuk, G., Plevritis, S.K., Glioblastoma multiforme: exploratory radiogenomic analysis by using quantitative image features. Radiology, 276, 2015, 313.
223. [223] Hatt, M., Tixier, F., Cheze Le Rest, C., Pradier, O., Visvikis, D., Robustness of intratumour (1)(8)F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma. Eur. J. Nucl. Med. Mol. Imaging 40 (2013), 1662–1671.
224. [224] Jain, R., Poisson, L.M., Gutman, D., Scarpace, L., Hwang, S.N., Holder, C.A., Wintermark, M., Rao, A., Colen, R.R., Kirby, J., Freymann, J., Jaffe, C.C., Mikkelsen, T., Flanders, A., Outcome prediction in patients with glioblastoma by using imaging, clinical, and genomic biomarkers: focus on the nonenhancing component of the tumor. Radiology 272 (2014), 484–493.
225. [225] Hunter, L.A., Krafft, S., Stingo, F., Choi, H., Martel, M.K., Kry, S.F., Court, L.E., High quality machine-robust image features: identification in nonsmall cell lung cancer computed tomography images. Med. Phys., 40, 2013, 121916.
226. [226] Leijenaar, R.T., Carvalho, S., Velazquez, E.R., van Elmpt, W.J., Parmar, C., Hoekstra, O.S., Hoekstra, C.J., Boellaard, R., Dekker, A.L., Gillies, R.J., Aerts, H.J., Lambin, P., Stability of FDG–PET Radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncol. (Stockh.) 52 (2013), 1391–1397.
227. [227] Parmar, C., Rios Velazquez, E., Leijenaar, R., Jermoumi, M., Carvalho, S., Mak, R.H., Mitra, S., Shankar, B.U., Kikinis, R., Haibe-Kains, B., Lambin, P., Aerts, H.J., Robust radiomics feature quantification using semiautomatic volumetric segmentation. PLoS One, 9, 2014, e102107.
228. [228] Buettner, R., Wolf, J., Thomas, R.K., Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 31 (2013), 1858–1865.
229. [229] Taguchi, F., Solomon, B., Gregorc, V., Roder, H., Gray, R., Kasahara, K., Nishio, M., Brahmer, J., Spreafico, A., Ludovini, V., Massion, P.P., Dziadziuszko, R., Schiller, J., Grigorieva, J., Tsypin, M., Hunsucker, S.W., Caprioli, R., Duncan, M.W., Hirsch, F.R., Bunn Jr., P.A., Carbone, D.P., Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J. Natl. Cancer Inst. 99 (2007), 838–846.
230. [230] Rizzo, S., Petrella, F., Buscarino, V., De Maria, F., Raimondi, S., Barberis, M., Fumagalli, C., Spitaleri, G., Rampinelli, C., De Marinis, F., Spaggiari, L., Bellomi, M., CT radiogenomic characterization of EGFR, K-RAS, and ALK mutations in non-small cell lung cancer. Eur. Radiol., 2015.
231. [231] Colen, R., Foster, I., Gatenby, R., Giger, M.E., Gillies, R., Gutman, D., Heller, M., Jain, R., Madabhushi, A., Madhavan, S., Napel, S., Rao, A., Saltz, J., Tatum, J., Verhaak, R., Whitman, G., NCI workshop report: clinical and computational requirements for correlating imaging phenotypes with genomics signatures. Transl. Oncol. 7 (2014), 556–569.
232. [232] Yaromina, A., Krause, M., Baumann, M., Individualization of cancer treatment from radiotherapy perspective. Mol. Oncol. 6 (2012), 211–221.
233. [233] Lindegaard, J.C., Overgaard, J., Bentzen, S.M., Pedersen, D., Is there a radiobiologic basis for improving the treatment of advanced stage cervical cancer?. J. Natl. Cancer Inst. Monogr., 1996, 105–112.
234. [234] Krause, M., Yaromina, A., Eicheler, W., Koch, U., Baumann, M., Cancer stem cells: targets and potential biomarkers for radiotherapy. Clin. Cancer Res. 17 (2011), 7224–7229.
235. [235] Yaromina, A., Krause, M., Thames, H., Rosner, A., Krause, M., Hessel, F., Grenman, R., Zips, D., Baumann, M., Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. Radiother. Oncol. 83 (2007), 304–310.
236. [236] Slonina, D., Gasinska, A., Intrinsic radiosensitivity of healthy donors and cancer patients as determined by the lymphocyte micronucleus assay. Int. J. Radiat. Biol. 72 (1997), 693–701.
237. [237] Menegakis, A., De Colle, C., Yaromina, A., Hennenlotter, J., Stenzl, A., Scharpf, M., Fend, F., Noell, S., Tatagiba, M., Brucker, S., Wallwiener, D., Boeke, S., Ricardi, U., Baumann, M., Zips, D., Residual gammaH2AX foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness. Radiother. Oncol., 2015.
238. [238] Menegakis, A., von Neubeck, C., Yaromina, A., Thames, H., Hering, S., Hennenlotter, J., Scharpf, M., Noell, S., Krause, M., Zips, D., Baumann, M., gammaH2AX assay in ex vivo irradiated tumour specimens: a novel method to determine tumour radiation sensitivity in patient-derived material. Radiother. Oncol., 2015.
239. [239] Fertil, B., Malaise, E.P., Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: analysis of 101 published survival curves. Int. J. Radiat. Oncol. Biol. Phys. 11 (1985), 1699–1707.
240. [240] Menegakis, A., Yaromina, A., Eicheler, W., Dorfler, A., Beuthien-Baumann, B., Thames, H.D., Baumann, M., Krause, M., Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by gammaH2AX staining. Int. J. Radiat. Biol. 85 (2009), 1032–1041.
241. [241] Bjork-Eriksson, T., West, C., Karlsson, E., Mercke, C., Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers. Int. J. Radiat. Oncol. Biol. Phys. 46 (2000), 13–19.
242. [242] Kahn, J., Hayman, T.J., Jamal, M., Rath, B.H., Kramp, T., Camphausen, K., Tofilon, P.J., The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. Neuro-Oncology 16 (2014), 29–37.
243. [243] Chitnis, M.M., Lodhia, K.A., Aleksic, T., Gao, S., Protheroe, A.S., Macaulay, V.M., IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination. Oncogene 33 (2014), 5262–5273.
244. [244] Du, S., Bouquet, S., Lo, C.H., Pellicciotta, I., Bolourchi, S., Parry, R., Barcellos-Hoff, M.H., Attenuation of the DNA damage response by transforming growth factor-beta inhibitors enhances radiation sensitivity of non-small-cell lung cancer cells in vitro and in vivo. Int. J. Radiat. Oncol. Biol. Phys. 91 (2015), 91–99.
245. [245] West, C.M., Davidson, S.E., Roberts, S.A., Hunter, R.D., The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br. J. Cancer 76 (1997), 1184–1190.
246. [246] El-Awady, R.A., Dikomey, E., Dahm-Daphi, J., Radiosensitivity of human tumour cells is correlated with the induction but not with the repair of DNA double-strand breaks. Br. J. Cancer 89 (2003), 593–601.
247. [247] Olive, P.L., Banath, J.P., Phosphorylation of histone H2AX as a measure of radiosensitivity. Int. J. Radiat. Oncol. Biol. Phys. 58 (2004), 331–335.
248. [248] Bartelink, H., Begg, A., Martin, J.C., van Dijk, M., Veer, L.v.'t., Vaart, P.v.d., Verheij, M., Towards prediction and modulation of treatment response. Radiother. Oncol. 50 (1999), 1–11.
249. [249] van Gisbergen, M.W., Voets, A.M., Starmans, M.H., de Coo, I.F., Yadak, R., Hoffmann, R.F., Boutros, P.C., Smeets, H.J., Dubois, L., Lambin, P., How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models. Mutat. Res. Rev. Mutat. Res. 764 (2015), 16–30.
250. [250] Begg, A.C., Predicting recurrence after radiotherapy in head and neck cancer. Semin. Radiat. Oncol. 22 (2012), 108–118.
251. [251] Smits, K.M., Melotte, V., Niessen, H.E., Dubois, L., Oberije, C., Troost, E.G., Starmans, M.H., Boutros, P.C., Vooijs, M., van Engeland, M., Lambin, P., Epigenetics in radiotherapy: where are we heading?. Radiother. Oncol. 111 (2014), 168–177.
252. [252] Hockel, M., Schlenger, K., Aral, B., Mitze, M., Schaffer, U., Vaupel, P., Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56 (1996), 4509–4515.
253. [253] Vaupel, P., Mayer, A., Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26 (2007), 225–239.
254. [254] Chouaib, S., Messai, Y., Couve, S., Escudier, B., Hasmim, M., Noman, M.Z., Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front. Immunol., 3, 2012, 21.
255. [255] Kaanders, J.H., Wijffels, K.I., Marres, H.A., Ljungkvist, A.S., Pop, L.A., van den Hoogen, F.J., de Wilde, P.C., Bussink, J., Raleigh, J.A., van der Kogel, A.J., Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. 62 (2002), 7066–7074.
256. [256] Nordsmark, M., Loncaster, J., Aquino-Parsons, C., Chou, S.C., Gebski, V., West, C., Lindegaard, J.C., Havsteen, H., Davidson, S.E., Hunter, R., Raleigh, J.A., Overgaard, J., The prognostic value of pimonidazole and tumour pO2 in human cervix carcinomas after radiation therapy: a prospective international multi-center study. Radiother. Oncol. 80 (2006), 123–131.
257. [257] Rouschop, K.M., van den Beucken, T., Dubois, L., Niessen, H., Bussink, J., Savelkouls, K., Keulers, T., Mujcic, H., Landuyt, W., Voncken, J.W., Lambin, P., van der Kogel, A.J., Koritzinsky, M., Wouters, B.G., The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J. Clin. Invest. 120 (2010), 127–141.
258. [258] Dubois, L.J., Lieuwes, N.G., Janssen, M.H., Peeters, W.J., Windhorst, A.D., Walsh, J.C., Kolb, H.C., Ollers, M.C., Bussink, J., van Dongen, G.A., van der Kogel, A., Lambin, P., Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 14620–14625.
259. [259] Peeters, S.G., Zegers, C.M., Yaromina, A., Van Elmpt, W., Dubois, L., Lambin, P., Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles. Q. J. Nucl. Med. Mol. Imaging 59 (2015), 39–57.
260. [260] Krause, B.J., Beck, R., Souvatzoglou, M., Piert, M., PET and PET/CT studies of tumor tissue oxygenation. Q. J. Nucl. Med. Mol. Imaging 50 (2006), 28–43.
261. [261] van Loon, J., De Ruysscher, D., Wanders, R., Boersma, L., Simons, J., Oellers, M., Dingemans, A.M., Hochstenbag, M., Bootsma, G., Geraedts, W., Pitz, C., Teule, J., Rhami, A., Thimister, W., Snoep, G., Dehing-Oberije, C., Lambin, P., Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int. J. Radiat. Oncol. Biol. Phys. 77 (2010), 329–336.
262. [262] West, C.M., Cooper, R.A., Loncaster, J.A., Wilks, D.P., Bromley, M., Tumor vascularity: a histological measure of angiogenesis and hypoxia. Cancer Res. 61 (2001), 2907–2910.
263. [263] Goethals, L., Perneel, C., Debucquoy, A., De Schutter, H., Borghys, D., Ectors, N., Geboes, K., McBride, W.H., Haustermans, K.M., A new approach to the validation of tissue microarrays. J. Pathol. 208 (2006), 607–614.
264. [264] Maciejewski, B., Withers, H.R., Taylor, J.M., Hliniak, A., Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation. Int. J. Radiat. Oncol. Biol. Phys. 16 (1989), 831–843.
265. [265] McKinley, E.T., Ayers, G.D., Smith, R.A., Saleh, S.A., Zhao, P., Washington, M.K., Coffey, R.J., Manning, H.C., Limits of [18F]-FLT PET as a biomarker of proliferation in oncology. PLoS One, 8, 2013, e58938.
266. [266] Petersen, C., Zips, D., Krause, M., Schone, K., Eicheler, W., Hoinkis, C., Thames, H.D., Baumann, M., Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. Int. J. Radiat. Oncol. Biol. Phys. 51 (2001), 483–493.
267. [267] Turesson, I., Nyman, J., Holmberg, E., Oden, A., Prognostic factors for acute and late skin reactions in radiotherapy patients. Int. J. Radiat. Oncol. Biol. Phys. 36 (1996), 1065–1075.
268. [268] Johansen, J., Bentzen, S.M., Overgaard, J., Overgaard, M., Evidence for a positive correlation between in vitro radiosensitivity of normal human skin fibroblasts and the occurrence of subcutaneous fibrosis after radiotherapy. Int. J. Radiat. Biol. 66 (1994), 407–412.
269. [269] West, C.M., Davidson, S.E., Elyan, S.A., Valentine, H., Roberts, S.A., Swindell, R., Hunter, R.D., Lymphocyte radiosensitivity is a significant prognostic factor for morbidity in carcinoma of the cervix. Int. J. Radiat. Oncol. Biol. Phys. 51 (2001), 10–15.
270. [270] Peacock, J., Ashton, A., Bliss, J., Bush, C., Eady, J., Jackson, C., Owen, R., Regan, J., Yarnold, J., Cellular radiosensitivity and complication risk after curative radiotherapy. Radiother. Oncol. 55 (2000), 173–178.
271. [271] Russell, N.S., Grummels, A., Hart, A.A., Smolders, I.J., Borger, J., Bartelink, H., Begg, A.C., Low predictive value of intrinsic fibroblast radiosensitivity for fibrosis development following radiotherapy for breast cancer. Int. J. Radiat. Biol. 73 (1998), 661–670.
272. [272] Russell, N.S., Arlett, C.F., Bartelink, H., Begg, A.C., Use of fluorescence in situ hybridization to determine the relationship between chromosome aberrations and cell survival in eight human fibroblast strains. Int. J. Radiat. Biol. 68 (1995), 185–196.
273. [273] Dileto, C.L., Travis, E.L., Fibroblast radiosensitivity in vitro and lung fibrosis in vivo: comparison between a fibrosis-prone and fibrosis-resistant mouse strain. Radiat. Res. 146 (1996), 61–67.
274. [274] Kiltie, A.E., Ryan, A.J., Swindell, R., Barber, J.B., West, C.M., Magee, B., Hendry, J.H., A correlation between residual radiation-induced DNA double-strand breaks in cultured fibroblasts and late radiotherapy reactions in breast cancer patients. Radiother. Oncol. 51 (1999), 55–65.
275. [275] Azria, D., Belkacemi, Y., Romieu, G., Gourgou, S., Gutowski, M., Zaman, K., Moscardo, C.L., Lemanski, C., Coelho, M., Rosenstein, B., Fenoglietto, P., Crompton, N.E., Ozsahin, M., Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncol. 11 (2010), 258–265.
276. [276] Bentzen, S.M., Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology. Nat. Rev. Cancer 6 (2006), 702–713.
277. [277] Rodemann, H.P., Bamberg, M., Cellular basis of radiation-induced fibrosis. Radiother. Oncol. 35 (1995), 83–90.
278. [278] Andreassen, C.N., Alsner, J., Overgaard, M., Sorensen, F.B., Overgaard, J., Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM—a study based on DNA from formalin fixed paraffin embedded tissue samples. Int. J. Radiat. Biol. 82 (2006), 577–586.
279. [279] Barnett, G.C., Thompson, D., Fachal, L., Kerns, S., Talbot, C., Elliott, R.M., Dorling, L., Coles, C.E., Dearnaley, D.P., Rosenstein, B.S., Vega, A., Symonds, P., Yarnold, J., Baynes, C., Michailidou, K., Dennis, J., Tyrer, J.P., Wilkinson, J.S., Gomez-Caamano, A., Tanteles, G.A., Platte, R., Mayes, R., Conroy, D., Maranian, M., Luccarini, C., Gulliford, S.L., Sydes, M.R., Hall, E., Haviland, J., Misra, V., Titley, J., Bentzen, S.M., Pharoah, P.D., Burnet, N.G., Dunning, A.M., West, C.M., A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiother. Oncol. 111 (2014), 178–185.
280. [280] Kerns, S.L., Ostrer, H., Stock, R., Li, W., Moore, J., Pearlman, A., Campbell, C., Shao, Y., Stone, N., Kusnetz, L., Rosenstein, B.S., Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African–American men after radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 78 (2010), 1292–1300.
281. [281] Kerns, S.L., Stock, R., Stone, N., Buckstein, M., Shao, Y., Campbell, C., Rath, L., De Ruysscher, D., Lammering, G., Hixson, R., Cesaretti, J., Terk, M., Ostrer, H., Rosenstein, B.S., A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 85 (2013), e21–e28.
282. [282] Kerns, S.L., Stock, R.G., Stone, N.N., Blacksburg, S.R., Rath, L., Vega, A., Fachal, L., Gomez-Caamano, A., Ruysscher, D.D., Lammering, G., Parliament, M., Blackshaw, M., Sia, M., Cesaretti, J., Terk, M., Hixson, R., Rosenstein, B.S., Ostrer, H., Genome-wide association study identifies a region on chromosome 11q14.3 associated with late rectal bleeding following radiation therapy for prostate cancer. Radiother. Oncol. 107 (2013), 372–376.
283. [283] Kerns, S.L., Stone, N.N., Stock, R.G., Rath, L., Ostrer, H., Rosenstein, B.S., A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of urinary symptoms after radiotherapy for prostate cancer. J. Urol. 190 (2013), 102–108.
284. [284] Chang-Claude, J., Popanda, O., Tan, X.L., Kropp, S., Helmbold, I., von Fournier, D., Haase, W., Sautter-Bihl, M.L., Wenz, F., Schmezer, P., Ambrosone, C.B., Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin. Cancer Res. 11 (2005), 4802–4809.
285. [285] Barnett, G.C., Coles, C.E., Elliott, R.M., Baynes, C., Luccarini, C., Conroy, D., Wilkinson, J.S., Tyrer, J., Misra, V., Platte, R., Gulliford, S.L., Sydes, M.R., Hall, E., Bentzen, S.M., Dearnaley, D.P., Burnet, N.G., Pharoah, P.D., Dunning, A.M., West, C.M., Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol. 13 (2012), 65–77.
286. [286] Fachal, L., Gomez-Caamano, A., Barnett, G.C., Peleteiro, P., Carballo, A.M., Calvo-Crespo, P., Kerns, S.L., Sanchez-Garcia, M., Lobato-Busto, R., Dorling, L., Elliott, R.M., Dearnaley, D.P., Sydes, M.R., Hall, E., Burnet, N.G., Carracedo, A., Rosenstein, B.S., West, C.M., Dunning, A.M., Vega, A., A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. Nat. Genet. 46 (2014), 891–894.
287. [287] Formenti, S.C., Demaria, S., Combining radiotherapy and cancer immunotherapy: a paradigm shift. J. Natl. Cancer Inst. 105 (2013), 256–265.
288. [288] Coulie, P.G., Van den Eynde, B.J., van der Bruggen, P., Boon, T., Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14 (2014), 135–146.
289. [289] Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science (New York, N.Y.) 348 (2015), 69–74.
290. [290] Rooney, M.S., Shukla, S.A., Wu, C.J., Getz, G., Hacohen, N., Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
291. [291] Mellman, I., Steinman, R.M., Dendritic cells: specialized and regulated antigen processing machines. Cell 106 (2001), 255–258.
292. [292] Demaria, S., Golden, E.B., Formenti, S.C., Role of local radiation therapy in cancer immunotherapy. JAMA Oncol., 2015.
293. [293] Golden, E.B., Chhabra, A., Chachoua, A., Adams, S., Donach, M., Fenton-Kerimian, M., Friedman, K., Ponzo, F., Babb, J.S., Goldberg, J., Demaria, S., Formenti, S.C., Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol. 16 (2015), 795–803.
294. [294] Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., Miller, M.L., Rekhtman, N., Moreira, A.L., Ibrahim, F., Bruggeman, C., Gasmi, B., Zappasodi, R., Maeda, Y., Sander, C., Garon, E.B., Merghoub, T., Wolchok, J.D., Schumacher, T.N., Chan, T.A., Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (New York, N.Y.) 348 (2015), 124–128.
295. [295] Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., Carcereny, E., Ahn, M.J., Felip, E., Lee, J.S., Hellmann, M.D., Hamid, O., Goldman, J.W., Soria, J.C., Dolled-Filhart, M., Rutledge, R.Z., Zhang, J., Lunceford, J.K., Rangwala, R., Lubiniecki, G.M., Roach, C., Emancipator, K., Gandhi, L., Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 2018–2028.
296. [296] Cammann, H., Jung, K., Meyer, H.A., Stephan, C., Avoiding pitfalls in applying prediction models, as illustrated by the example of prostate cancer diagnosis. Clin. Chem. 57 (2011), 1490–1498.
297. [297] Legare, F., Stacey, D., Briere, N., Desroches, S., Dumont, S., Fraser, K., Murray, M.A., Sales, A., Aube, D., A conceptual framework for interprofessional shared decision making in home care: protocol for a feasibility study. BMC Health Serv. Res., 11, 2011, 23.
298. [298] Elwyn, G., O'Connor, A., Stacey, D., Volk, R., Edwards, A., Coulter, A., Thomson, R., Barratt, A., Barry, M., Bernstein, S., Butow, P., Clarke, A., Entwistle, V., Feldman-Stewart, D., Holmes-Rovner, M., Llewellyn-Thomas, H., Moumjid, N., Mulley, A., Ruland, C., Sepucha, K., Sykes, A., Whelan, T., Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ, 333, 2006, 417.
299. [299] Elwyn, G., Laitner, S., Coulter, A., Walker, E., Watson, P., Thomson, R., Implementing shared decision making in the NHS. BMJ, 341, 2010, c5146.
300. [300] Tariman, J.D., Berry, D.L., Cochrane, B., Doorenbos, A., Schepp, K., Preferred and actual participation roles during health care decision making in persons with cancer: a systematic review. Ann. Oncol. 21 (2010), 1145–1151.
301. [301] Molenaar, S., Sprangers, M.A., Postma-Schuit, F.C., Rutgers, E.J., Noorlander, J., Hendriks, J., de Haes, H.C., Feasibility and effects of decision aids. Med. Decis. Mak. 20 (2000), 112–127.
302. [302] Kasper, J.F., Mulley, A.G. Jr., Wennberg, J.E., Developing shared decision-making programs to improve the quality of health care. QRB Qual. Rev. Bull. 18 (1992), 183–190.
303. [303] O'Connor, A.M., Rostom, A., Fiset, V., Tetroe, J., Entwistle, V., Llewellyn-Thomas, H., Holmes-Rovner, M., Barry, M., Jones, J., Decision aids for patients facing health treatment or screening decisions: systematic review. BMJ 319 (1999), 731–734.
304. [304] Masya, L.M., Young, J.M., Solomon, M.J., Harrison, J.D., Dennis, R.J., Salkeld, G.P., Preferences for outcomes of treatment for rectal cancer: patient and clinician utilities and their application in an interactive computer-based decision aid. Dis. Colon Rectum 52 (2009), 1994–2002.
305. [305] Molenaar, S., Sprangers, M.A., Rutgers, E.J., Luiten, E.J., Mulder, J., Bossuyt, P.M., van Everdingen, J.J., Oosterveld, P., de Haes, H.C., Decision support for patients with early-stage breast cancer: effects of an interactive breast cancer CDROM on treatment decision, satisfaction, and quality of life. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 19 (2001), 1676–1687.
306. [306] Stalmeier, P.F., Unic, I.J., Verhoef, L.C., Van Daal, W.A., Evaluation of a shared decision making program for women suspected to have a genetic predisposition to breast cancer: preliminary results. Med. Decis. Mak. 19 (1999), 230–241.
307. [307] Stacey, D., Legare, F., Col, N.F., Bennett, C.L., Barry, M.J., Eden, K.B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., Trevena, L., Wu, J.H., Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst. Rev., 1, 2014, CD001431.
308. [308] Andre, F., Delaloge, S., First-generation genomic tests for breast cancer treatment. Lancet Oncol. 11 (2010), 6–7.
309. [309] Gray, R.G., Quirke, P., Handley, K., Lopatin, M., Magill, L., Baehner, F.L., Beaumont, C., Clark-Langone, K.M., Yoshizawa, C.N., Lee, M., Watson, D., Shak, S., Kerr, D.J., Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 29 (2011), 4611–4619.
310. [310] Ahmed, K.A., Fulp, W.J., Berglund, A.E., Hoffe, S.E., Dilling, T.J., Eschrich, S.A., Shridhar, R., Torres-Roca, J.F., Differences between colon cancer primaries and metastases using a molecular assay for tumor radiation sensitivity suggest implications for potential oligometastatic SBRT patient selection. Int. J. Radiat. Oncol. Biol. Phys. 92 (2015), 837–842.
311. [311] Eschrich, S., Zhang, H., Zhao, H., Boulware, D., Lee, J.-H., Bloom, G., Torres-Roca, J.F., Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. Int. J. Radiat. Oncol. Biol. Phys. 75 (2009), 497–505.
312. [312] Eschrich, S.A., Fulp, W.J., Pawitan, Y., Foekens, J.A., Smid, M., Martens, J.W., Echevarria, M., Kamath, V., Lee, J.H., Harris, E.E., Bergh, J., Torres-Roca, J.F., Validation of a radiosensitivity molecular signature in breast cancer. Clin. Cancer Res. 18 (2012), 5134–5143.
313. [313] Eschrich, S.A., Pramana, J., Zhang, H., Zhao, H., Boulware, D., Lee, J.-H., Bloom, G., Rocha-Lima, C., Kelley, S., Calvin, D.P., Yeatman, T.J., Begg, A.C., Torres-Roca, J.F., A gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation. Int. J. Radiat. Oncol. Biol. Phys. 75 (2009), 489–496.
314. [314] Anker, C.J., Wo, J.Y., Personalized medicine in radiation oncology–a work in progress. Int. J. Radiat. Oncol. Biol. Phys. 92 (2015), 843–845.
315. [315] Hood, L., Friend, S.H., Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat. Rev. Clin. Oncol. 8 (2011), 184–187.
316. [316] Khoury, M.J., Gwinn, M.L., Glasgow, R.E., Kramer, B.S., A population approach to precision medicine. Am. J. Prev. Med. 42 (2012), 639–645.
317. [317] Weston, A.D., Hood, L., Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J. Proteome Res. 3 (2004), 179–196.